Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...

Shares of Travere Therapeutics Inc. surged over 13% Tuesday afternoon, reaching their highest level since October 2022 and ...

Wells Fargo analyst Mohit Bansal notes Travere Therapeutics (TVTX) plans to submit on Phase 3 DUPLEX study after FDA meeting. The company plans ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer ...

Read Our Latest Stock Analysis on TVTX Travere Therapeutics Stock Down 0.5 % Shares of TVTX opened at $18.37 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to ...

The United States market has been flat in the last week, but it has risen by 20% over the past 12 months, with earnings expected to grow by 15% per annum in the coming years. In this environment, ...

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate ...